Trial · NCT02032823
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Invasive Disease Free Survival (IDFS) | Olaparib | 106 | Participants | ||
| Invasive Disease Free Survival (IDFS) | Placebo | 178 | Participants | ||
| Distant Disease Free Survival (DDFS) | Olaparib | 89 | Participants | ||
| Distant Disease Free Survival (DDFS) | Placebo | 152 | Participants | ||
| Overall Survival (OS) | Olaparib | 75 | Participants | ||
| Overall Survival (OS) | Placebo | 109 | Participants | ||
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Olaparib | Contralateral invasive breast cancer | 31 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Placebo | Contralateral invasive breast cancer | 40 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Olaparib | Contralateral non-invasive breast cancer | 3 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Placebo | Contralateral non-invasive breast cancer | 4 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Olaparib | New primary ovarian cancer | 3 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Placebo | New primary ovarian cancer | 9 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Olaparib | New primary fallopian tube cancer | 1 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Placebo | New primary fallopian tube cancer | 4 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Olaparib | New primary peritoneal cancer | 0 | Participants | |
| Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer | Placebo | New primary peritoneal cancer | 0 | Participants | |
| Change From Baseline for FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) Score for Participants Who Completed Neoadjuvant Chemotherapy | Olaparib | Change from baseline FACIT-Fatigue Score to 6 months | -1.5 | 95% Confidence Interval -2.3 to -0.8 | Scores on a scale |
| Change From Baseline for FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) Score for Participants Who Completed Neoadjuvant Chemotherapy | Placebo | Change from baseline FACIT-Fatigue Score to 6 months | -0.2 | 95% Confidence Interval -1.0 to 0.6 | Scores on a scale |
| Change From Baseline for FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) Score for Participants Who Completed Neoadjuvant Chemotherapy | Olaparib | Change from baseline FACIT-Fatigue Score to 12 months | -1.5 | 95% Confidence Interval -2.4 to -0.6 | Scores on a scale |
| Change From Baseline for FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) Score for Participants Who Completed Neoadjuvant Chemotherapy | Placebo | Change from baseline FACIT-Fatigue Score to 12 months | 0.0 | 95% Confidence Interval -0.9 to 0.9 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02032823/results